Cat. # | Size | Qty. | Price |
---|---|---|---|
33636S | 100 µl |
|
REACTIVITY | H M |
SENSITIVITY | Endogenous |
MW (kDa) | 70 |
Source/Isotype | Rabbit IgG |
Product Information
MW (kDa) | 70 |
Application | Dilution |
---|---|
Western Blotting | 1:1000 |
For western blots, incubate membrane with diluted primary antibody in 5% w/v BSA, 1X TBS, 0.1% Tween® 20 at 4°C with gentle shaking, overnight.
NOTE: Please refer to primary antibody product webpage for recommended antibody dilution.
NOTE: Prepare solutions with reverse osmosis deionized (RODI) or equivalent grade water.
Load 20 µl onto SDS-PAGE gel (10 cm x 10 cm).
NOTE: Loading of prestained molecular weight markers (#59329, 10 µl/lane) to verify electrotransfer and biotinylated protein ladder (#7727, 10 µl/lane) to determine molecular weights are recommended.
NOTE: Volumes are for 10 cm x 10 cm (100 cm2) of membrane; for different sized membranes, adjust volumes accordingly.
Do not add Anti-biotin, HRP-linked Antibody for detection of biotinylated protein markers. There is no need. The Streptavidin-HRP will also visualize the biotinylated markers.
* Avoid repeated exposure to skin.
posted June 2005
revised June 2020
Protocol Id: 266
Human, Mouse
Mouse, Rat
Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues near the amino terminus of human Sox9 protein.
Sox9 is a transcription factor with an HMG-box DNA binding domain that has homology to the HMG domain of the mammalian testis-determining factor, SRY (1). Sox9 regulates several important processes during embryonic development including chondrogenesis, during which it contributes to skeletal formation and digit specification (2,3). Sox9 also coordinates with steroidogenic factor-1 to direct Sertoli cell-specific expression of anti-Mullerian hormone during embryogenesis, thereby contributing to male sex determination (4). In addition, Sox9 is reportedly involved in the maintenance of adult stem cell populations, including multipotent neural stem cells (5), hair follicle stem cells (6), and mammary stem cells (7). Recent interest has focused on the role of Sox9 in tumor biology. For example, research studies have shown that Sox9 expression in lung adenocarcinoma induces a mesenchymal phenotype in tumor cells (8). Other research studies have shown that YAP1 induced upregulation of Sox9 confers cancer stem cell like properties on esophageal cancer cells (9). Moreover, Sox9 expression has been linked with several other tumor types including ovarian, prostate, and pancreatic malignancies (10-12).
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.